Venous thromboembolism prevention in cancer patients: the search for common antecedents

Bibliography

• PRANDONI P, FALANGA A, PICCIOLI A: Cancer and venous thromboembolism. Lancet Oncol. (2005) 6:401-410.
   PubMed Web of Science ®Google Scholar
• HEIT JA: Cancer and venous thromboembolism: scope of the problem. Cancer Control. (2005) 12(Suppl. 1):5-10.
   PubMedGoogle Scholar
• LEE A, LEVINE M: Venous thromboembolism and cancer: risks and outcomes. Circulation (2003) 107:I17-I21.
   Web of Science ®Google Scholar
• BICK RL: Cancer-associated thrombosis. N. Engl. J. Med. (2003) 349:109-111.
   PubMed Web of Science ®Google Scholar
• SORENSEN HT, MELLEMKJAER L, OLSEN JH, BARON JA: Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. (2000) 343:1846-1850.
   PubMed Web of Science ®Google Scholar
• SORENSEN HT, JOHNSEN SP, NORGARD B, ZACHARSKI LR, BARON JA: Cancer and venous thromboembolism: a multidisciplinary approach. Clin. Lab. (2003) 49:615-623.
   PubMedGoogle Scholar
• CHEW HK, WUN T, HARVEY D, ZHOU H, WHITE RH: Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch. Intern. Med. (2006) 166:458-464.
   PubMed Web of Science ®Google Scholar
• ZACHARSKI LR: Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Semin. Thromb. Hemost. (2003) 29:239-246.
   PubMed Web of Science ®Google Scholar
• ZACHARSKI LR: Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathy. Cancer Lett. (2002) 186:1-9.
   PubMed Web of Science ®Google Scholar
• GEERTS WH, PINEO GF, HEIT JA et al.: Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest (2004) 126(3 Suppl.):S338-S400.
   PubMedGoogle Scholar
• STEIN P, BEEMATH A, MEYERS F, SKAF E, SANCHEZ J, OLSON R: Incidence of venous thromboembolism in patients hospitalized with cancer. Am. J. Med. (2006) 119:60-68.
   PubMed Web of Science ®Google Scholar
• THODIYIL P, KAKKAR A: Variation in relative risk of venous thrombembolism in different cancers. J. Thromb. Haemost. (2002) 87:1076-1077.
   Google Scholar
• BLOM JW, VANDERSCHOOT JP, OOSTINDIER MJ, OSANT S, VAN DER MEER FJ, ROSENDAAL FR: Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J. Thromb. Haemost. (2006) 4:529-535.
   PubMed Web of Science ®Google Scholar
• KHORANA A, FRANCIS C, CULAKOVA E, LYMAN G: Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer (2005) 104:2822-2829.
   PubMed Web of Science ®Google Scholar
• HUSSEIN MA: Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb. Haemost. (2006) 95:924-930.
   PubMed Web of Science ®Google Scholar
• LIN A, RYU J, HARVEY D, SIERACKI B, SCUDDER S, WUN T: Low-dose warfarin does not decrease the rate of thrombosis in patients with cervix and vulvo-vaginal cancer treated with chemotherapy, radiation, and erythropoietin. Gynecol. Oncol. (2006) 102:98-102.
   PubMed Web of Science ®Google Scholar
• JACOBSON G, KAMATH R, SMITH B, GOODHEART M: Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol. Oncol. (2005) 96:470-474.
   PubMed Web of Science ®Google Scholar
• LAVEY R, LIU PY, GREER B et al.: Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB – IVA carcinoma of the cervix: a Southwest Oncology Group Study. Gynecol. Oncol. (2004) 95:145-151.
   PubMed Web of Science ®Google Scholar
• ROSENZWEIG MQ, BENDER CM, LUCKE JP, YASKO JM, BRUFSKY AM: The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J. Pain Symptom Manage. (2004) 27:185-190.
   PubMed Web of Science ®Google Scholar
• DEITCHER SR, GOMES MP: The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer (2004) 101:439-449.
   PubMed Web of Science ®Google Scholar
• WHITE RH, CHEW HK, ZHOU H et al.: Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch. Intern. Med. (2005) 165:1782-1787.
   PubMed Web of Science ®Google Scholar
• MONREAL M, PRANDONI P: Venous thromboembolism as first manifestation of cancer. Semin. Thromb. Hemost. (1999) 25:131-136.
   PubMed Web of Science ®Google Scholar
• BONA RD, HICKEY AD, WALLACE DM: Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis. Am. J. Clin. Oncol. (2000) 23:71-73.
   PubMed Web of Science ®Google Scholar
• HUTTEN BA, PRINS MH, GENT M et al.: Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J. Clin. Oncol. (2000) 18:3078-3083.
   PubMed Web of Science ®Google Scholar
• PALARETI G, LEGNANI C, LEE A et al.: A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with and without malignancy. Thromb. Haemost. (2000) 84:805-810.
   PubMed Web of Science ®Google Scholar
• PRANDONI P, LENSING AWA, PICCIOLI A et al.: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 100:3484-3488.
   PubMed Web of Science ®Google Scholar
• LEVINE MN: Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer. Cancer Treat. Rev. (2002) 28:145-149.
   PubMed Web of Science ®Google Scholar
• LEE AY: Treatment of venous thromboembolism in cancer patients. Thromb. Res. (2001) 102:V195-V208.
   Google Scholar
• AGENO W, SQUIZZATO A, GARCIA D, IMBERTI D: Epidemiology and risk factors of venous thromboembolism. Semin. Thromb. Hemost. (2006) 32:651-658.
   PubMed Web of Science ®Google Scholar
• GOMES MP, DEITCHER SR: Diagnosis of venous thromboembolic disease in cancer patients. Oncology (2003) 17:126-35.
   PubMed Web of Science ®Google Scholar
• OUDEGA R, HOES AW, TOLL DB, MOONS KG: The value of clinical findings and D-dimer tests in diagnosing deep vein thrombosis in primary care. Semin. Thromb. Hemost. (2006) 32:673-677.
   PubMed Web of Science ®Google Scholar
• BLOM JW, DOGGEN CJ, OSANTO S, ROSENDAAL FR: Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA (2005) 293:715-722.
   PubMed Web of Science ®Google Scholar
• ZACHARSKI L, PRANDONI P, MONREAL M: Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist (2005) 10:72-79.
   PubMed Web of Science ®Google Scholar
• HIRSH J, FUSTER V, ANSELL J et al.: American heart association/American college of cardiology foundation guide to warfarin therapy. Circulation (2003) 107:1692-1711.
   PubMed Web of Science ®Google Scholar
• LINKINS L, CHOI PT, DOUKETIS JD: Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann. Intern. Med. (2003) 139:893-900.
   PubMed Web of Science ®Google Scholar
• HIRSH J, RASCHKE R: Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest (2004) 126(3 Suppl.):S188-S203.
   PubMed Web of Science ®Google Scholar
• BICK RL: Cancer-associated thrombosis: focus on extended therapy with dalteparin. J. Support Oncol. (2006) 4:115-20.
   PubMedGoogle Scholar
• LEE AY: The role of low-molecular-weight heparins in treating thrombosis. J. Support Oncol. (2006) 4:123-124.
   PubMedGoogle Scholar
• PRANDONI P: Low-molecular-weight heparins for the long-term treatment of cancer patients with venous thromboembolism. J. Support Oncol. (2006) 4:127-128.
   PubMedGoogle Scholar
• MEYER G, MARJANOVIC Z, VALCKE J et al.: Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch. Intern. Med. (2002) 162:1729-1735.
   PubMed Web of Science ®Google Scholar
• HULL R, PINEO G, MAH AF et al.: A randomised trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Blood (2002) 100:A148.
   PubMed Web of Science ®Google Scholar
• DEITCHER SR, KESSLER CM, MERLI G et al.: Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomised study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proc. Am. Soc. Clin. Oncol. (2003) 22:761.
   Google Scholar
• LEE AY, LEVINE MN, BAKER RI et al.: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. (2003) 349:146-153.
   PubMed Web of Science ®Google Scholar
• KAKKAR AK, LEVINE MN, KADZIOLA Z et al.: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J. Clin. Oncol. (2004) 10:1944-1948.
   Web of Science ®Google Scholar
• LEE A, RICKLES F, JULIAN J et al.: Randomized comparision of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J. Clin. Oncol. (2005) 23:2123-2129.
   PubMed Web of Science ®Google Scholar
• KLERK CP, SMORENBURG SM, OTTEN HM et al.: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. (2005) 23:2130-2135.
   PubMed Web of Science ®Google Scholar
• ZACHARSKI LR, Ornstein DL: Heparin and cancer. Thromb. Haemost. (1998) 80:10-23.
   PubMed Web of Science ®Google Scholar
• ALTINBAS M, COSKUN HS, ER O et al.: A randomized clinical trial of combination chemotherapy with and without low-molecular weight heparin in small cell lung cancer. J. Thromb. Haemost. (2004) 2:1266-1271.
   PubMed Web of Science ®Google Scholar
• HRON G, EICHINGER S, WELTERMANN A, QUEHENBERGER P, HALBMAYER WM, KYRLE PA: Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J. Thromb. Haemost. (2006) 4:752-756.
   PubMed Web of Science ®Google Scholar
• HRON G, KOLLARS M, BINDER BR, EICHINGER S, KYRLE PA: Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA (2006) 296:397-402.
   PubMed Web of Science ®Google Scholar
• HULL RD, PINEO GF, BRANT RF et al.; LITE Trial Investigators: Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am. J. Med. (2007) 120:72-82.
   PubMed Web of Science ®Google Scholar
• ICLI F, AKBULUT H, UTKAN G et al.: Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J. Surg. Oncol. (2006) (Published online).
   Google Scholar
• PRANDONI P, LENSING AW, PESAVENTO R: New strategies for the treatment of acute venous thromboembolism. Semin. Thromb. Hemost. (2006) 32:787-792.
   PubMed Web of Science ®Google Scholar
• MAHAFFEY KW, BECKER RC: The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapy. Circulation (2006) 114:2313-2316.
   PubMed Web of Science ®Google Scholar
• ERIKSSON BI, BORRIS LC, DAHL OE et al.: ODIXa-HIP study investigators. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation (2006) 114:2374-2381.
   PubMed Web of Science ®Google Scholar
• MYERS DD JR, HENKE PK, BEDARD PW et al.: Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J. Vasc. Surg. (2006) 44:625-632.
   PubMed Web of Science ®Google Scholar
• POLGAR J, MATUSKOVA J, WAGNER DD: The P-selectin, tissue factor, coagulation triad. J. Thromb. Haemost. (2005) 3:1590-1596.
   PubMed Web of Science ®Google Scholar
• HRON G, KOLLARS M, WEBER H et al.: Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb. Haemost. (2007) 97:119-123.
   PubMed Web of Science ®Google Scholar
• MILLER GJ, BAUER KA, HOWARTH DJ, COOPER JA, HUMPHRIES SE, ROSENBERG RD: Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J. Thromb. Haemost. (2004) 2:2107-2114.
   PubMed Web of Science ®Google Scholar
• ZACHARSKI LR, CHOW BK, HOWES PS et al.: Effect of reduction of iron (Fe) stores on cardiovascular and cancer outcomes in patients with advanced peripheral arterial disease (PAD): VA Cooperative Study #410, The Iron (Fe) and Atherosclerosis Study (FeAST). Blood (2006) 108:A512 (Abstract 1807).
   Google Scholar
• ZACHARSKI LR, ORNSTEIN DL, WOLOSHIN S, SCHWARTZ LM: Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am. Heart J. (2000) 140:98-104.
   PubMed Web of Science ®Google Scholar
• ZACHARSKI LR, CHOW BK, HOWES PS, SHAMAYEVA G, LAVORI PW: Implementation of an iron reduction protocol in patients with peripheral vascular disease: VA cooperative study #410: the Iron and Atherosclerosis Study. Am. Heart J. (2004) 148:386-392.
   PubMed Web of Science ®Google Scholar
• ZACHARSKI LR, CHOW BK, HOWES PS et al.: Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA (2007) 297:603-610.
   PubMed Web of Science ®Google Scholar
• SEMERARO N, COLUCCI M: Tissue factor in health and disease. Thromb. Haemost. (1997) 78:759-764.
   PubMed Web of Science ®Google Scholar
• RICKLES FR, PATIERNO S, FERNANDEZ PM: Tissue factor, thrombin, and cancer. Chest (2003) 124(3 Suppl.):S58-S68.
   PubMed Web of Science ®Google Scholar
• LWALEED BA, FRANCIS JL, CHISHOLM M: Monocyte tissue factor levels in cancer patients. Saudi Med. J. (2000) 21:722-729.
   PubMed Web of Science ®Google Scholar
• MILLER CL, GRAZIANO C, LIM RC, CHIN M: Generation of tissue factor by patient monocytes: correlation to thromboembolic complications. Thromb. Haemost. (1981) 46:489-495.
   PubMed Web of Science ®Google Scholar
• ASAKURA H, KAMIKUBO Y, GOTO A et al.: Role of tissue factor in disseminated intravascular coagulation. Thromb. Res. (1995) 80:217-224.
   PubMed Web of Science ®Google Scholar
• GARNER B, ROBERG K, BRUNK UT: Endogenous ferritin protects cells with iron-laden lysosomes against oxidative stress. Free Radic. Res. (1998) 29:103-114.
   PubMed Web of Science ®Google Scholar
• SCHAFER FQ, QIAN SY, BUETTNER GR: Iron and free radical oxidations in cell membranes. Cell Mol. Biol. (Noisy-le-grand) (2000) 46:657-662.
   PubMed Web of Science ®Google Scholar
• RICE-EVANS C, BURDON R: Free radical–lipid interactions and their pathological consequences. Prog. Lipid Res. (1993) 32:71-110.
   PubMed Web of Science ®Google Scholar
• POLACK B, PERNOD G, BARRO C, DOUSSIERE J: Role of oxygen radicals in tissue factor induction by endotoxin in blood monocytes. Haemostasis (1997) 27:193-200.
   PubMedGoogle Scholar
• BRAND K, BANKA CL, MACKMAN N, TERKELTAUB RA, FAN ST, CURTISS LK: Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. Arterioscler. Thromb. (1994) 14:790-797.
   PubMedGoogle Scholar
• FEI H, BERLINER JA, PARHAMI F, DRAKE TA: Regulation of endothelial cell tissue factor expression by minimally oxidized LDL and lipopolysaccharide. Arterioscler. Thromb. (1993) 13:1711-1717.
   PubMed Web of Science ®Google Scholar
• LESNIK P, DENTAN C, VONICA A, MOREAU M, CHAPMAN MJ: Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell- and copper-mediated oxidation. Arterioscler. Thromb. Vasc. Biol. (1995) 15:1121-1130.
   PubMed Web of Science ®Google Scholar
• ISHII H, TEZUKA T, ISHIKAWA H, TAKADA K, OIDA K, HORIE S: Oxidized phospholipids in oxidized low-density lipoprotein down-regulate thrombomodulin transcription in vascular endothelial cells through a decrease in the binding of RARb-RXRa heterodimers and Sp1 and Sp3 to their binding sequences in the TM promoter. Blood (2003) 101:4765-4774.
   PubMed Web of Science ®Google Scholar
• KOO SW, CASPER KA, OTTO KB, GIRA AK, SWERLICK RA: Iron chelators inhibit VCAM-1 expression in human dermal microvascular endothelial cells. J. Invest. Dermatol. (2003) 120:871-879.
   PubMed Web of Science ®Google Scholar
• BROZNA JP, HORAN M, CARSON SD: Dipyridamole inhibits O2-release and expression of tissue factor activity by peripheral blood monocytes stimulated with lipopolysaccharide. Thromb. Res. (1990) 60:141-156.
   PubMed Web of Science ®Google Scholar
• HERMANN M, KAPIOTIS S, HOFBAUER R et al.: Salicylate inhibits LDL oxidation initiated by superoxide/nitric oxide radicals. FEBS Lett. (1999) 445:212-214.
   PubMed Web of Science ®Google Scholar
• EXNER M, HERMANN M, HOFBAUER R et al.: The salicylate metabolite gentisic acid, but not the parent drug, inhibits glucose autoxidation-mediated atherogenic modification of low density lipoprotein. FEBS Lett. (2000) 470:47-50.
   PubMed Web of Science ®Google Scholar
• SALONEN JT, KORPELA H, NYYSSONEN K et al.: Lowering of body iron stores by blood letting and oxidation resistance of serum lipoproteins: a randomized cross-over trial in male smokers. J. Int. Med. (1995) 237:161-168.
   PubMed Web of Science ®Google Scholar
• VAN JAARSVELD J, POOL GF: Beneficial effects of blood donation on high density lipoprotein concentration and the oxidative potential of low density lipoprotein. Atherosclerosis (2002) 16:395-402.
   Google Scholar
• ANDERS MJ, LIFESO RM, LANDIS M, MIKULSKY J, MEINKING C, MCCRACKEN KS: Effect of preoperative donation of autologous blood on deep-vein thrombosis following total joint arthroplasty of the hip or knee. J. Bone Joint Surg. Am. (1996) 78:574-580.
   PubMedGoogle Scholar
• MCCOLL M, TAIT RC, WALKER ID, PERRY DJ, MCCALL F, CONKIE JA: Low thrombosis rate seen in blood donors and their relatives with inherited deficiencies of antithrombin and protein C: correlation with type of defect, family history, and absence of the factor V Leiden mutation. Blood Coagul. Fibrinol. (1996) 7:689-694.
   PubMed Web of Science ®Google Scholar
• WELLS PS, BLAJCHMAN MA, HENDERSON P et al.: Prevalence of antithrombin deficiency in healthy blood donors: a cross-sectional study. Am. J. Hematol. (1994) 45:321-324.
   PubMed Web of Science ®Google Scholar
• COLE P, RODU B: Descriptive epidemiology: cancer statistics. In: Cancer: Principles and Practice of Oncology. DeVita VT, Hellman S, Rosenberg SA (Eds), 6th Edition, Lippincott Williams & Wilkins, Philadelphia (2001):228-241.
   Google Scholar
• DI MINNO G, TUFANO A: Challenges in the prevention of venous thromboembolism in the elderly. J. Thromb. Haemost. (2004) 2:1292-1298.
   PubMed Web of Science ®Google Scholar
• KYRLE PA, MINAR E, BIALONCZYK C, HIRSCHL M, WELTERMANN A, EICHINGER S: The risk of recurrent venous thromboembolism in men and women. N. Engl. J. Med. (2004) 350:2558-2563.
   PubMed Web of Science ®Google Scholar
• SKIBBER JM, MINSKY BD, HOFF PM: Cancer of the colon. In: Cancer: Principles and Practice of Oncology. DeVita VT, Hellman S, Rosenberg SA (Eds), 6th Edition, Lippincott Williams & Wilkins, Philadelphia (2001):1216-1271.
   Google Scholar
• KEARON C, SALZMAN EW, HIRSH J: Epidemiology, pathogenesis, and natural history of venous thrombosis. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (Eds), 4th Edition, Lippincott Williams & Wilkins, New York (2001):1153-1177.
   Google Scholar
• HEIT JA: The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. Chest (2003) 124(3 Suppl.):S40-S48.
   Google Scholar
• MOSTAFA G, MATTHEWS BD, NORTON HJ, KERCHER KW, SING RF, HENIFORD BT: Influence of demographics on colorectal cancer. Am. Surg. (2004) 70:259-264.
   PubMed Web of Science ®Google Scholar
• WEI EK, GIOVANNUCCI E, WU K et al.: Comparison of risk factors for colon and rectal cancer. Int. J. Cancer (2004) 108:433-442.
   PubMed Web of Science ®Google Scholar
• KOTAKE K, HONJO S, SUGIHARA K et al.: Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis. Colon Rectum (2003) 46(10 Suppl.):S32-S43.
   Google Scholar
• DOMINITZ JA, SAMSA GP, LANDSMAN P, PROVENZALE D: Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. Cancer (1998) 82:2312-2320.
   PubMed Web of Science ®Google Scholar
• WEINBERG ED: Iron in neoplastic disease. Nutr. Cancer (1983) 4:223-233.
   PubMedGoogle Scholar
• WU T, SEMPOS CT, FREUDENHEIM JL, MUTI P, SMIT E: Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann. Epidemiol. (2004) 14:195-201.
   PubMed Web of Science ®Google Scholar
• WEINBERG ED: The role of iron in cancer. Eur. J. Cancer Prev. (1996) 5:19-36.
   PubMed Web of Science ®Google Scholar
• HUANG X: Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat. Res. (2003) 533:153-171.
   PubMed Web of Science ®Google Scholar
• GEIER D, HEBERT B, POTTI A: Risk of primary non-hepatocellular malignancies in hereditary hemochromatosis. Anticancer Res. (2002) 22:3797-3799.
   PubMed Web of Science ®Google Scholar
• DEUGNIOR Y, LOREAL O: Iron as a carcinogen. In: Hemochromatosis: Genetics, Pathopyhysiology, Diagnosis and Treatment. Barton JC, Edwards CQ (Eds), Cambridge University Press, New York, NY (2000):239-249.
   Google Scholar
• MCBRIDE TJ, PRESTON BD, LOEB LA: Mutagenic spectrum resulting from DNA damage by oxygen radicals. Biochemistry (1991) 30:207-213.
   PubMed Web of Science ®Google Scholar
• KEYER K, IMLAY JA: Superoxide accelerates DNA damage by elevating free-iron levels. Proc. Natl. Acad. Sci. USA (1996) 93:13635-13640.
   PubMed Web of Science ®Google Scholar
• ABATE C, PATEL L, RAUSCHER FJ III, CURRAN T: Redox regulation of fos and jun DNA-binding activity in vitro. Science (1990) 249:1157-1161.
   PubMed Web of Science ®Google Scholar
• NORRBY K, MATTSBY-BALTZER I, INNOCENTI M, TUNEBERG S: Orally administered bovine lactoferrin systemically inhibits VEGF(165)-mediated angiogenesis in the rat. Int. J. Cancer (2001) 91:236-240.
   PubMed Web of Science ®Google Scholar
• MAXWELL PH, RATCLIFFE PJ: Oxygen sensors and angiogenesis. Semin. Cell Dev. Biol. (2002) 13:29-37.
   PubMed Web of Science ®Google Scholar
• LE NT, RICHARDSON DR: The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim. Biophys. Acta (2002) 1603:31-46.
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR, LE NT: Iron chelators with high anti-proliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a novel link between iron metabolism and proliferation. Blood (2004) [Epub ahead of print].
   Google Scholar
• FEGER F, FERRY-DUMAZET H, MAMANI MATSUDA M et al.: Role of iron in tumor cell protection from the pro-apoptotic effect of nitric oxide. Cancer Res. (2001) 61:5289-5294.
   PubMed Web of Science ®Google Scholar
• WEINBERG JB, HIBBS JB Jr: Endocytosis of red blood cells or haemoglobin by activated macrophages inhibits their tumoricidal effect. Nature (1977) 269:245-247.
   PubMed Web of Science ®Google Scholar
• MERK K, MATTSSON B, HPLM G, GULLBRING B, BJORKHOLM M: The incidence of cancer among blood donors. Int. J. Epidemiol. (1990) 19:505-509.
   PubMed Web of Science ®Google Scholar
• MEYERS DG, JENSEN KC, MENITOVE JE: A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion (2002) 42:1135-1139.
   PubMed Web of Science ®Google Scholar
• LOVEJOY DB, RICHARDSON DR: Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr. Med. Chem. (2003) 10:1035-1049.
   PubMed Web of Science ®Google Scholar